# A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

> **NCT02616666** · PHASE4 · COMPLETED · sponsor: **University of Liverpool** · enrollment: 632 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT02616666
- **Lead sponsor:** University of Liverpool
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-25
- **Primary completion:** 2025-12-12
- **Final completion:** 2025-12-12
- **Target enrollment:** 632 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616666, "A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02616666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*